CHMP, which is Europe's equivalent of the Food and Drug Administration's advisory panel
The end of the week brought fantastic news for shareholders in Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) who witnessed the CHMP recommending approval for Nuedexta, it's already U.S.-approved treatment for psuedobulbar affect. An approval in Europe would be a key win for Avanir as Nuedexta currently makes up the majority of its revenue. In addition, it's worth noting that the European Medicine Agency's panel recommended two dosing regimens, potentially broadening in patient reach. Shares reacted notably higher but tapered off by the end of the day on Friday. Although the EMA isn't required to follow the recommendation of its panel, this would be a case where I'd be mildly surprised if it didn't.
hey there kutz. true arena and avanir both have high short interest. although arena does have more shares outstanding than avanir. i own both companies. avanir did trade up about 22% at the high than pulled back a little from there. more short games. fun to watch the arena and avanir shorts get hammered one day